

GLAXOSMITHKLINE PLC  
Form 6-K  
December 24, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending December 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

This  
announcement replaces  
the original announcements  
released on  
6 May 2008  
at 16.30 ;  
4 August 20  
08  
at 18.11  
;  
and  
7 November 20  
08  
at 18.02  
.

The Administrators of the GlaxoSmithKline Performance Share Plan (the "Plan") notified the Company on 8 December 2008 of a correction to the market price of Ordinary shares used to calculate the number of shares reinvested under the dividend reinvestment element of the Plan for participants who both received Ordinary shares and who were detailed in the affected original announcements, in respect of dividends paid to shareholders on 10 July 2008

.  
The market price of Ordinary shares should have read £11.21 (rather than £11.20), and the participants' increased interests in Ordinary shares have been corrected.

Given the cumulative nature of dividend reinvestment, the correction in respect of the payment made on 10 July 2008 also had a minor impact on the calculation of the dividends reinvested for the affected Plan participants in respect of the payments made on 9 October 2008 and 8 January 2009

.  
Details in respect of JP Garnier, C Viehbacher and SM Werner are excluded from these replacements as JP Garnier and C Viehbacher are no longer directors of the Company, and SM Werner is no longer deemed a Person Discharging Managerial Responsibility.

Save as disclosed above, all other details remain unchanged.

**Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons**

The administrators of the GlaxoSmithKline Performance Share Plan  
(the "Administrators")  
notified the Company and  
the under  
-mentioned  
person  
s  
on  
6 May  
2008

of  
an  
increase in  
their notional  
interests

in  
Ordinary  
shares  
at a price of £  
11.21  
per share  
and  
Ordinary  
Share  
ADRs at  
a price of \$  
44.11  
per ADR

following the notional re-investment of the dividend  
paid to shareholders on  
10 July 2008

	<b>Ordinary shares</b>	<b>ADRs</b>
Mr A P Witty	4,600.76	
Mr J S Heslop	3,738.77	
Dr M M Slaoui	332.61	1
		657.54

Mrs C E Bruck Slaoui	26.51	37.72
Mr J M Clarke	2,787.62	
Mr M Dunoyer	1,049.88	
Mr E J Gray	870.19	
Mr R G Greig		917.26
Mr D Learmouth	573.25	
Mr W C Louv		666.68
Mr D J Phelan		1,412.58
Dr D Pulman		917.26

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to  
transaction

s  
notified in accordance with  
Disclosure and Transparency R  
ule  
s 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

6 May 2008

**Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons**

The administrators of the GlaxoSmithKline Performance Share Plan (the "Administrators") notified the Company and the under-mentioned persons on 4 August 2008 of an increase in their notional interests in Ordinary shares at a price of £11.67 per share and Ordinary Share ADRs at a price of \$ 46.53 per ADR

following the notional re-investment of the dividend paid to shareholders on 9 October 2008.

	<b>Ordinary shares</b>	<b>ADRs</b>
Mr A P Witty	5,161.32	
Mr J S Heslop	3,633.05	

Dr M M Slaoui	323.20	1,591.48
Mrs C E Bruck Slaoui	25.76	36.21
Mr S M Bicknell	272.17	
Mr J M Clarke	2,708.79	
Mr M Dunoyer	1,020.19	
Mr E J Gray	845.58	
Mr S A Hussain	500.36	
Mr D Learmouth	557.04	
Mr W C Louv		640.11
Mr D		1,356.28
J		
Phelan		
Dr D Pulman		880.70
Mr D S Redfern	415.11	
Mr J R Stéphenne	935.76	
Ms C Thomas	312.39	

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to  
transaction

s  
notified in accordance with  
Disclosure and Transparency R  
ule  
s 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

4 August 2008

### **Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

The administrators of the GlaxoSmithKline Performance Share Plan (the "Administrators") notified the  
Company and  
the under-mentioned

person

s

on 7 November  
2008 of an increase in their notional interest

s

in Ordinary shares at a price of £

11.66

per share and Ordinary Share ADRs at a price of \$37.32 per ADR

following the notional re-investment of the dividend  
to be  
paid to shareholders on  
8 January 2009

	<b>Ordinary shares</b>	<b>ADRs</b>
Mr A P Witty	5,625.	
	08	
Mr J S Heslop	3,959.49	
Dr M M Slaoui	352.24	1,835.07
Mrs C E Bruck Slaoui	28.07	41.75
Mr S M Bicknell	296.63	
Mr J M Clarke	2,952.18	
Mr M Dunoyer	1,111.86	
Mr E J Gray	921.56	
Mr S A Hussain	545.32	
Mr D Learmouth	607.09	
Mr W C Louv		738.09
Mr D J Phelan		1,563.87
Dr D Pulman		1015.50
Mr D S Redfern	452.41	
Mr J R Stéphenne	1,019.84	
Ms C Thomas	340.46	

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transactions notified in accordance with

Disclosure and Transparency Requirements

ule  
s  
3.1.4R(1)(a)  
.

Victoria A Whyte  
Deputy  
Company Secretary

7 November 2008

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: December 24, 2008

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc